SAB Biotherapeutics, Inc.: 5%+ holders

As of November 6, 2026, 10 holders' latest Schedule 13D or 13G filings report owning 5% or more of SAB Biotherapeutics, Inc. The largest reported stake is Vivo Opportunity Fund Holdings, L.P.'s, at 9.99%. 22 filings are on record since October 3, 2025 (Schedule 13G/A, August 14, 2026).

Caligan Partners LP also filed stake reports on 9 other companies ↓

Sell to companies like SAB Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Latest 2026-08-14 · Holder: Commodore Capital LP · Percent: 9.9% · Shares: 8,948,170 · SCHEDULE 13G/A
• Filing 2026-08-14 · Reporting person: Vivo Opportunity Fund Holdings, L.P. · Sole voting: 22,637,108 · Shared voting: 0 · Sole dispositive: 22,637,108 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Balyasny Asset Management L.P. · Sole voting: 7,225,439 · Shared voting: 0 · Sole dispositive: 7,225,439 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Caligan Partners LP · Sole voting: 0 · Shared voting: 7,967,207 · Sole dispositive: 0 · Shared dispositive: 7,967,207 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 6,627,501 · Sole dispositive: 0 · Shared dispositive: 6,627,501 · SCHEDULE 13G/A, 2026-08-14

SAB Biotherapeutics, Inc. has 22 Schedule 13D or 13G filings on record since 2025-10-03. 10 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind SAB Biotherapeutics, Inc. and the warning signs.

See SAB Biotherapeutics, Inc.'s free Snapshot Watch SAB Biotherapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on SAB Biotherapeutics, Inc. and the records around it.

SAB Biotherapeutics, Inc. elsewhere on the record

• Form D filing Aug 2025
• Who owns it

Companies that share a holder

• Caligan Partners LP also filed stake reports on 9 other companies: Avalo Therapeutics, Inc. (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026)
• Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
• Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)

Want the whole picture on SAB Biotherapeutics, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on SAB Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on SAB Biotherapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   23 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies SAB Biotherapeutics, Inc. by CUSIP 78397T202 and gives its principal executive office as 777 W 41st St, Suite 401, Miami Beach, FL 33140 (SCHEDULE 13G/A, 2026-08-14).

What the percentages are based on

Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 9.45% of the Shares, based on the 76,464,094 Shares outstanding as of May 6, 2026, as reported in the Issuer's report filed on form 10-Q with the Securities and Exchange Commission on May 12, 2026.Balyasny Asset Management L.P., SCHEDULE 13G/A, 2026-08-14

Timeline

Swipe the table sideways to see every column.

Questions about who owns SAB Biotherapeutics, Inc.

Who owns SAB Biotherapeutics, Inc.?

On this page, 10 holders' latest ownership filings report 5% or more of SAB Biotherapeutics, Inc.: Vivo Opportunity Fund Holdings, L.P. (9.99%, Schedule 13G/A, filed 2026-08-14), RA Capital Management, L.P. (9.9%, Schedule 13D/A, filed 2026-08-10), Commodore Capital LP (9.9%, Schedule 13G/A, filed 2026-08-14), Balyasny Asset Management L.P. (9.45%, Schedule 13G/A, filed 2026-08-14) and Bvf Partners L P (9.1%, Schedule 13G/A, filed 2026-02-17); 5 more are listed above.

Who are the largest shareholders of SAB Biotherapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of SAB Biotherapeutics, Inc. on this page are Vivo Opportunity Fund Holdings, L.P. (9.99%), RA Capital Management, L.P. (9.9%) and Commodore Capital LP (9.9%).

When did Vivo Opportunity Fund Holdings, L.P. buy into SAB Biotherapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Vivo Opportunity Fund Holdings, L.P. on this page is the Schedule 13G, filed 2025-10-03, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.99%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 22 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for SAB Biotherapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for SAB Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when SAB Biotherapeutics, Inc. is mentioned again
• Find former SAB Biotherapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes